학술논문
Intravitreal Faricimab for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration
ORIGINAL RESEARCH
ORIGINAL RESEARCH
Document Type
Academic Journal
Author
Source
Clinical Ophthalmology. December 31, 2022, Vol. 16, p4041, 6 p.
Subject
Language
English
ISSN
1177-5483
Abstract
Introduction Intravitreal therapies neutralizing vascular endothelial growth factor (VEGF) have considerably reduced the extent of vision loss in patients with neovascular age-related macular degeneration (nAMD). (1) Nevertheless, there exist a [...]
Purpose: To evaluate the short-term effects of intravitreal faricimab (IVF) in treatment-resistant neovascular age- related macular degeneration (nAMD) subjects previously treated with intravitreal aflibercept (IVA). Methods: A retrospective review was conducted on nAMD patients undergoing IVA therapy at a single private practice institution. Subjects were divided into Study and Control groups. Both Study and Control subjects had undergone [greater than or equal to] 6 IVA treatments during the previous 12 months, [greater than or equal to] 4 IVA treatments during the previous 6 months, had a central macular thickness (CMT) on optical coherence tomography (OCT) of [greater than or equal to] 300 microns, and had observable intraretinal and/or subretinal fluid on OCT prior to group assignment. Study subjects were switched from IVA to IVF and received 3 treatments within 4 months. Control subjects remained on IVA during the same time period and received 3 treatments within 4 months. Results: There were a total of 55 subjects analyzed. There were 39.3% (11/28) in the Study Group and 7.4% (2/27) in the Control Group attaining a CMT of less than 300 microns without retinal fluid on OCT at the end of the 4-month study period (p = 0.004). There were 35.7% (10/28) in the Study Group and 7.4% (2/27) in the Control Group gaining 2 or more lines of visual acuity at the end of the 4-month study period (p = 0.008). Conclusion: IVF can improve the visual and anatomic outcomes in a significant minority of treatment-resistant nAMD subjects previously managed with IVA. A greater follow-up period is needed to determine if such improvements can be maintained. Keywords: faricimab, neovascular age-related macular degeneration, recalcitrance, treatment-resistants
Purpose: To evaluate the short-term effects of intravitreal faricimab (IVF) in treatment-resistant neovascular age- related macular degeneration (nAMD) subjects previously treated with intravitreal aflibercept (IVA). Methods: A retrospective review was conducted on nAMD patients undergoing IVA therapy at a single private practice institution. Subjects were divided into Study and Control groups. Both Study and Control subjects had undergone [greater than or equal to] 6 IVA treatments during the previous 12 months, [greater than or equal to] 4 IVA treatments during the previous 6 months, had a central macular thickness (CMT) on optical coherence tomography (OCT) of [greater than or equal to] 300 microns, and had observable intraretinal and/or subretinal fluid on OCT prior to group assignment. Study subjects were switched from IVA to IVF and received 3 treatments within 4 months. Control subjects remained on IVA during the same time period and received 3 treatments within 4 months. Results: There were a total of 55 subjects analyzed. There were 39.3% (11/28) in the Study Group and 7.4% (2/27) in the Control Group attaining a CMT of less than 300 microns without retinal fluid on OCT at the end of the 4-month study period (p = 0.004). There were 35.7% (10/28) in the Study Group and 7.4% (2/27) in the Control Group gaining 2 or more lines of visual acuity at the end of the 4-month study period (p = 0.008). Conclusion: IVF can improve the visual and anatomic outcomes in a significant minority of treatment-resistant nAMD subjects previously managed with IVA. A greater follow-up period is needed to determine if such improvements can be maintained. Keywords: faricimab, neovascular age-related macular degeneration, recalcitrance, treatment-resistants